---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001188"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:24:50.311024+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arbutus and Genevant file 5 international patent lawsuits against Moderna; terminate sublicense for breach

## Summary
- Agreement entitles Arbutus to damages specifically allocated to Moderna's mRESVIA in pending U.S. litigation; if no allocation, parties discuss in good faith.
- Arbutus terminated 2016 sublicense with ModernaTX for material breach over unpaid milestone/royalty payments; 60-day cure period.
- Five lawsuits filed in Canada, Japan, Switzerland, and two UPC actions covering 30 countries, seeking injunctions and monetary relief against Spikevax and mRESVIA.
- U.S. jury trial against Moderna in Delaware currently scheduled for September 2025.

## SEC filing metadata
- accession: 0001171843-25-001188
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001188/0001171843-25-001188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001188/f8k_030325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001188
- JSON: https://secwatch.observer/filing/0001171843-25-001188.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.